Table 2 Characteristics of patients enrolled in therapeutic trials following molecular profiling
All trials | Genotype-matched | Genotype-unmatched | p value | |
|---|---|---|---|---|
Median age (range) | 58 (18–81) | 58 (24–81) | 58.5 (18–80) | NS |
Female/Male | 205/72 | 64/25 | 141/47 | NS |
Median prior systemic therapies (range) | 2 (1–16) | 2 (1–11) | 2 (1–16) | NS |
Tumor type (number of patients) | ||||
Breast | 47 | 22 | 25 | NS |
Colorectal | 43 | 18 | 25 | |
Lung | 48 | 18 | 30 | |
Gynecological | 91 | 22 | 69 | |
Other | 48 | 9 | 39 | |
Genotyping platform (number of patients) | ||||
MALDI-TOF MS panel | 176 | 61 | 115 | NS |
TruSeq Amplicon cancer panel | 101 | 28 | 73 | |
Ampliseq cancer panel | 0 | 0 | 0 | |
Trial phase (number of patients) | ||||
Phase I | 158 | 72 | 86 | <0.001 |
Phase II | 67 | 9 | 58 | |
Phase III | 52 | 8 | 44 | |
Investigational agent(s) (number of patients) | ||||
Targeted monotherapy | 112 | 23 | 89 | <0.001 |
Targeted drug combination | 87 | 59 | 28 | |
Targeted drug and chemotherapy | 43 | 7 | 36 | |
Immunotherapy | 34 | 0 | 34 | |
Radiotherapy | 1 | 0 | 1 | |